We are Olema
Oncology.

Committed, tireless, and persistent.

We are committed to the discovery, development, and commercialization of a transformational generation of targeted therapies for women’s cancers.

Our team spent more than a decade conducting research, and has a deep insight into, endocrine-driven cancers. OP-1250 was the result of that persistence–the first compound designed to realize the Olema vision.

Our Team leadership board of directors

leadership

board of directors

leadership

Sean P. Bohen, M.D., Ph.D. President and CEO

Cyrus Harmon, Ph.D. Chief Technology Officer

Pamela M. Klein, M.D. Chief Medical Officer

Peter Kushner, Ph.D. Chief Scientific Officer

Shane Kovacs Chief Operating and Financial Officer

David C. Myles, Ph.D. Chief Development Officer

Kinney Horn Chief Business Officer

John B. Moriarty Jr., J.D. Executive Vice President and Chief Legal Officer

Leslie Hodges Gallagher, Ph.D. Senior Vice President, Discovery Biology

Sean P. Bohen, M.D., Ph.D. President and CEO

Ian Clark Chairman of the Board

Cindy Butitta Member

Sandra J. Horning, M.D., FACP, FASCO Member

Frank McCormick, Ph.D., F.R.S., D.Sc (Hon) Member

Andy Rappaport Member

Gorjan Hrustanovic, Ph.D. Member

Graham Walmsley, M.D., Ph.D. Member

Cyrus Harmon, Ph.D. Chief Technology Officer

Julie Dexter Vice President and Head of People

Demiana Faltaos, PharmD, Ph.D Vice President, Head of Clinical Pharmacology

David Kulp, PhD Vice President, Research Informatics

Florence Zhu, CPA Vice President, Finance & Controller

Our Science

We have a clear-eyed recognition of the limitations of current therapies and strategies, but have no intention of limiting what comes next.

Learn More

Our Pipeline

Olema has completed discovery and preclinical studies of OP-1250 required to file an IND and has begun clinical phase research. We anticipate exploring the potential applicability of OP-1250 in a range of metastatic breast cancers, as well as estrogen-driven gynecologic cancers.

Learn More

Press Releases

Here are the latest press releases from Olema.

For further information, visit Investors & Media.

Here are the latest press releases from Olema.

For further information, visit Investors & Media.

February 23rd, 2021 Olema Oncology to Participate at Upcoming Virtual Investor Conferences SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will
December 17th, 2020 Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P.
December 7th, 2020 Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to
November 23rd, 2020 Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closing of its previously
November 19th, 2020 Olema Oncology Announces Pricing of Initial Public Offering SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial
November 13th, 2020 Olema Oncology Appoints Biopharma Industry Veteran Sandra J. Horning, M.D., to Board of Directors Former Chief Medical Officer of Roche Brings Expertise in Both Oncology Drug Development and Academic Medicine SAN FRANCISCO , Nov. 13, 2020 /PRNewswire/ -- Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies
February 23rd, 2021 Olema Oncology to Participate at Upcoming Virtual Investor Conferences SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that it will
December 17th, 2020 Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P.
December 7th, 2020 Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two posters relating to
November 23rd, 2020 Olema Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the closing of its previously
November 19th, 2020 Olema Oncology Announces Pricing of Initial Public Offering SAN FRANCISCO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the pricing of its initial
November 13th, 2020 Olema Oncology Appoints Biopharma Industry Veteran Sandra J. Horning, M.D., to Board of Directors Former Chief Medical Officer of Roche Brings Expertise in Both Oncology Drug Development and Academic Medicine SAN FRANCISCO , Nov. 13, 2020 /PRNewswire/ -- Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies

We are Olema Oncology.

Committed, tireless, and persistent.

We are Olema
Oncology.